CVS Health Corp (CVS)

81.56
NYSE : Health Care
Prev Close 82.70
Day Low/High 81.31 / 83.43
52 Wk Low/High 69.30 / 106.67
Avg Volume 8.57M
Exchange NYSE
Shares Outstanding 1.07B
Market Cap 88.73B
EPS 4.70
P/E Ratio 17.85
Div & Yield 2.00 (2.40%)

Latest News

The Pain Before the Gains: Cramer's 'Mad Money' Recap (Thursday 1/19/17)

The Pain Before the Gains: Cramer's 'Mad Money' Recap (Thursday 1/19/17)

Don't worry about a little selloff, says Jim Cramer. The data and earnings signal an improving economy.

EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks

EpiPen Competitor Auvi-Q Will Return in February, but It'll Cost Insurance Companies Big Bucks

The autoinjector will be free for insured patients and those whose annual income is less than $100,000.

Trifecta Stocks Weekly Roundup

We initiated one new position and trimmed/added to several others as December-quarter earnings season kicked off.

Biotech Premarket Movers: SGMO, IPXL, PTLA

Biotech Premarket Movers: SGMO, IPXL, PTLA

Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.

Mylan Crushed by Trump, Cigna and CVS -- All In Two Days

Mylan Crushed by Trump, Cigna and CVS -- All In Two Days

The drug maker's shares have fallen 6.2% since Wednesday's market open.

CVS Is the Latest to Rock Mylan's EpiPen Empire

CVS Is the Latest to Rock Mylan's EpiPen Empire

The price of EpiPens has surged about 25% annually since 2007.

Cigna Defends Abandoning EpiPen Coverage

Cigna Defends Abandoning EpiPen Coverage

Cigna will now encourage patients to use either Impax's or Mylan's generic autoinjector. Impax offers cheaper prices, but can its manufacturing keep up?

CVS Health Offers Patients Lowest Cash Price In The Market For Generic Epinephrine Auto-injector To Treat Allergic Reactions

CVS Health Offers Patients Lowest Cash Price In The Market For Generic Epinephrine Auto-injector To Treat Allergic Reactions

Generic epinephrine auto-injector from Impax Laboratories available at CVS Pharmacy at cash price 80% lower than EpiPen®

CVS Shares Could Make Your Portfolio Sick

CVS Shares Could Make Your Portfolio Sick

Shares of CVS have taken a hit over the past year, and while the company is doing what it can to stem the slide, it hasn't been enough.

Why CVS Could Be Lethal for Your Otherwise Healthy Portfolio

Why CVS Could Be Lethal for Your Otherwise Healthy Portfolio

Avoid at all costs.

Trifecta Stocks Weekly Roundup

The market continued its run as the new year started, with a number of portfolio positions showing nice advances.

Walgreens Beats on Bottom Line

The company's consistency is a testament to management’s commitment to and focus on continued cost improvements and self-help initiatives exclusive of the Rite Aid merger.

Drugstore Chain CVS Poised for a Rebound

Drugstore Chain CVS Poised for a Rebound

CVS has cash on hand and is benefiting from recent acquisitions.

Trifecta Stocks Weekly Roundup

As 2016 comes to a close, we have ample cash in the portfolio to take advantage of any near-term pullback in the market.

Trifecta Stocks Weekly Roundup

We used available cash to scale into 2 portfolio positions before the Christmas holiday.

Longtime Holding CVS May Be Long in the Tooth

We might have this one on the chopping block soon, so be ready for that alert should it come out.

Find Last Minute Holiday Gifts And Essentials At CVS Pharmacy

Find Last Minute Holiday Gifts And Essentials At CVS Pharmacy

With an assortment of last minute gift ideas, stocking stuffers and everyday essentials, CVS Pharmacy takes the stress out of holiday shopping and entertaining

Trifecta Stocks Portfolio: Rate Hike, A Fed Story

Trifecta Stocks Portfolio: Rate Hike, A Fed Story

During a week that brought the long-awaited Fed interest rate increase, we exited one portfolio position.

Trifecta Stocks Weekly Roundup

During the week, we downgraded one stock's rating and exited a position as indices showed mixed performance.

How to Create Your Own Bargain

How to Create Your Own Bargain

CVS Health is an example of using LEAP options to manufacture a great entry point.

Jim Cramer's 'Mad Money' Recap: How to Play Leapfrog in This Fast-Moving Market

Jim Cramer's 'Mad Money' Recap: How to Play Leapfrog in This Fast-Moving Market

Jim Cramer says stocks keep leapfrogging their peers in sectors like airlines and semiconductors.

CVS Posts 2017 Guidance in Line With Estimates; Share Prices Fall

CVS Posts 2017 Guidance in Line With Estimates; Share Prices Fall

The retail pharmacy and pharmacy benefit manager saw shares fall 1.7% ahead of market's open Thursday.

CVS Posts 2017 Guidance

CVS Posts 2017 Guidance

Company officials highlighted CVS' diversified lines of business as a way to manage political changes.

Downgrading CVS Health on This Morning's Analyst Day Press Release

We believe 2017 will be another challenging year for CVS, and we expect the stock to remain rangebound.

CVS Continues To Heal Its Damage

We are watching this name closely to ensure fundamentals are sound.

CVS Health Makes Overdose-Reversal Drug Available Without A Prescription At All CVS Pharmacy Locations In Nevada

CVS Health Makes Overdose-Reversal Drug Available Without A Prescription At All CVS Pharmacy Locations In Nevada

More than 100 CVS Pharmacy locations in Nevada can now dispense naloxone

So-So Retail Sales for November

Still, the latest government data are largely favorable to the retail-related holdings in our portfolio.